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Vitamin D Deficiency in Renal 
Disease
Jean Jeanov Filipov and Emil Paskalev Dimitrov
Abstract
Vitamin D deficiency is highly prevalent in patients with renal disease. The 
abnormal vitamin D (VD) metabolism in chronic kidney disease (CKD) is a key fac-
tor for developing CKD-related mineral bone disease (CKD-MBD), which directly 
influences the survival of the CKD patients. The importance of VD is perhaps of 
greater value due to its pleiotropic effects that span beyond calcium-phosphorus 
metabolism (cancer protection, diabetes prevention, and renal protection). The aim 
of our chapter is to depict the clinical implications of VD deficiency in the setting 
of CKD, including VD pleiotropy in renal disease, and to propose the most adequate 
treatment suggested in the literature.
Keywords: vitamin D deficiency, chronic kidney disease, mineral bone disease, 
vitamin D pleiotropy, vitamin D supplementation
1. Introduction
Vitamin D (VD) deficiency is a growing problem worldwide [1]. Due to the 
wide distribution of the vitamin D receptor in human body, the effect of VD spans 
beyond calcium-phosphorus and bone metabolism—VD deficiency is associated 
with higher prevalence of hypertension, diabetes mellitus, and neoplasia [2]. As 
kidneys play an important role in the metabolism of VD, patients with chronic kid-
ney disease (CKD) are at increased risk for VD deficiency. The aim of our chapter 
is to demonstrate the clinical implications of vitamin D deficiency in CKD and 
to outline the possible treatment options in this group of patients. In our review, 
a stress is laid on clinical trials due to their greater relevance to everyday clinical 
practice, compared to in vitro and animal models.
2.  Definition: vitamin D deficiency, vitamin D sufficiency, chronic 
kidney disease
VD status is being evaluated via the serum level of 25-hydroxyvitamin D 
(25VD)—the metabolite formed in the first hydroxylation in the liver, due to its 
longer half-life (approx. 3 weeks), compared to the active metabolite 1,25-dihy-
droxyvitamin D (1,25VD) (4–6 hours). The best options for 25VD serum level 
evaluation methods are high performance liquid chromatography (HPLC) and 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). There are reports, 
discussing the use of free 25VD as indicator of VD status. However, in renal disease, 
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the ratio between free and total 25VD remained unchained; therefore, total 25VD is 
the indicator of VD status in CKD [3].
Generally, 25VD level has reverse association with parathyroid hormone (PTH) 
levels. In addition, higher 25VD is associated with higher calcium intestinal reab-
sorption. However, at 25VD ≥ 75 nmol/l, no reduction in PTH levels and no increase 
in calcium intestinal reabsorption occurs [4, 5]. Therefore, 25VD ≥ 75 nmol/l is 
regarded as a cut-off value for vitamin D sufficiency.
No generally accepted definition for VD deficiency exists, as authors choose cut-off 
value either serum 25VD of 25 nmol/L [6] or serum 25VD of 50 nmol/L [7]. However, 
target levels of 75 nmol/L are recommended, taking into consideration the clinical 
importance of mild VD insufficiency (25VD between 50 and 74.9 nmol/L) [7, 8].
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure 
or function, present for more than 3 months, with implications for health [one 
of the following: estimated glomerular filtration rate (eGFR) less than 60 ml/
min/1.73 m2,presence of proteinuria, structural abnormalities of the kidney 
detected on imaging, pathological findings detected on kidney biopsy, urine 
sediment pathology, electrolyte abnormalities due to tubular disorders, history of 
kidney transplantation] [9]. CKD patients are at increased risk for VD deficiency; 
therefore, they require VD screening [7].
3. Vitamin D metabolism in health and renal disease
3.1 VD metabolism in healthy subjects
VD is synthesized predominantly endogenously (approx. to 90% of the total 
VD in human body). In the skin, the ultraviolet light transforms 7-dehydroxycho-
lesterol (provitamin D) to pre-vitamin D, which under the influence of body tem-
perature spontaneously isomerizes to cholecalciferol (vitamin D3). Approximately, 
10% of total body VD is taken orally (vitamin D2, ergocalciferol, and cholecalcif-
erol). VD is transported via VD-binding protein to the liver, where it is hydroxyl-
ated to 25VD. The next step in VD activation is hydroxylation of 25VD by the 
enzyme 1α-hydroxylase (CYP27B1) to 1,25VD, which is the active VD metabolite. 
The process occurs predominantly in the renal tubules. In addition, non-renal 
CYP27B1 was detected in skin (basal keratinocytes and hair follicles), lymph nodes 
(granulomata), colon (epithelial cells and parasympathetic ganglia), pancreas 
(islets), adrenal medulla, brain (cerebellum and cerebral cortex), prostate epithe-
lial cells, and placenta (decidual and trophoblastic cells) [10], indicating the wider 
significance of the VD metabolites. Finally, 1,25VD is inactivated by the enzyme 
24-hydroxylaze.
1,25VD exerts its effect via the vitamin D receptor (VDR), which is detected in 
all human organs. 1,25VD binds to VDR, the complex forms a heterodimer with 
the receptor for retinoid X (RXR) within the nucleus. The 1,25VD-VDR-RXR 
complex binds to vitamin D reacting elements, modulating gene expression. The 
highest expression of VDR is detected in bones, small intestines, and parathyroid 
gland. VDR activation leads to influencing bone metabolism), increase of calcium 
and phosphate absorption, and PTH secretion suppression. However, due to the 
wider VDR distribution in human body, its activation is associated with effects 
beyond influencing calcium-phosphorus metabolism–renin-angiotensin system 
(RAS) suppression and cardiac hypertrophy prevention (myocardial VDR), diabe-
tes mellitus control (pancreatic VDR), and immune system modulation (VDR in 
the immune cells).
The above-mentioned stages of VD metabolism form the so called VD axis.
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3.2 VD metabolism in CKD
All levels of VD metabolism are significantly affected in renal disease.
Cholecalciferol synthesis is reduced in uremic skin. In addition, these patients 
are usually older, with reduced exposure to sunlight, which is additionally associ-
ated with poorer skin VD synthesis. What is more, oral VD intake is decreased due 
to protein intake reduction.
25VD is reduced in CKD due to reduced amount of its precursor, increased loss 
in nephrotic patients, and 25VD sequestration in adipose tissue due to higher rate of 
obesity in CKD patients [11, 12].
Even during the initial stages of CKD (eGFR below 60 ml/min/1.73 m2) due to 
reduced phosphate tubular excretion, higher levels of fibroblast growth factor 23 
(FGF-23) occur, which suppress CYP27B1 activity. Furthermore, phosphatemia and 
metabolic acidosis decrease enzyme activity too. In addition, 1,25VD levels in renal 
disease are reduced because of increased catabolism due to increased FGF-23 levels. 
Finally, the smaller number of functioning tubules is directly associated with lower 
1,25VD production in advanced CKD.
VDR is affected in CKD too. Low 1,25VD downregulates of VDR expression [13]. 
In areas of nodular growth in the parathyroid gland reduced VDR content is detected. 
In uremia, there is significant decrease in VDR-RXR binding to vitamin D reacting 
elements, as well as reduced RXR content in the parathyroid glands, explaining 
increased PTH levels without the presence of hypocalcaemia and hyperphosphatemia 
[14]. Hypocalcaemia in advanced CKD increases the parathyroid levels of calreticulin, 
a cytosolic protein that binds the DNA-binding domain of nuclear receptors, thus 
blocking VDR-mediated transactivation. Higher levels of inflammatory cytokines 
were found to be associated with impaired binding of VDR-RXR to vitamin D 
VD axis Healthy subjects In CKD
Cholecalciferol/ergocalciferol Skin synthesis from 
UV light or oral intake
• Reduced skin synthesis (age, 
uremia, reduced UV exposure)
• Reduced oral intake
25-hydroxyvitamin D(25VD) Hepatic synthesis 
(25-hydroxylase)
• Reduced amount of its precursor
• Increased loss in nephrotic 
patients
• 25VD sequestration in adipose 
tissue
1,25-dihydroxyvitamin D(1,25VD) Hydroxylation 
in renal tubules 
(1α-hydroxylase) and 
other organs
• Increased catabolism
• Suppressed 1α-hydroxylase 
activity
• Reduced synthesis in renal tubules 
in advanced CKD
Vitamin D receptor(VDR) Widely spread 
in human body, 
esp. bone and 
parathyroid glands 
(calcium-phosphorus 
metabolism)
In all other organs 
(pleiotropy)
• Downregulated expression (low 
1,25VD, hypocalcaemia)
• Impaired binding to VDRE 
(uremia, inflammatory cytokines, 
etc.)
• Reduced VDR content in parathy-
roid glands (hypertrophy)
CKD, chronic kidney disease; VDRE, vitamin D reacting elements; UV, ultraviolet.
Table 1. 
Vitamin D axis in health and in renal disease.
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reacting elements, contributing to vitamin D resistance in patients on hemodialysis 
[15]. Finally, hypocalcaemia in CKD suppresses the calcium-sensing receptor (CaSR) 
in the parathyroid glands, which in turn downregulates parathyroid VDR expression; 
use of calcimimetics upregulated VDR expression in rat models [16].
The VD axis in health and renal disease is depicted in Table 1.
4. Vitamin D deficiency: clinical implications in renal disease
The major mechanisms for abnormal VD metabolism and VD deficiency were 
outlined in the section above. Of particular importance is hyperphosphatemia, 
caused by initial renal damage, leading to higher FGF-23 levels, which in turn 
suppresses CYP27B1 activity and increases 1,25VD catabolism. Suboptimal VD 
levels are the basis of the abnormal calcium-phosphate metabolism in renal disease. 
Currently, the term CKD-associated mineral bone disorder (CKD-MBD) is used 
to define the wide spectrum of CKD-related abnormalities in calcium-phosphate 
metabolism, as their importance spans beyond bone health.
4.1 CKD-associated mineral bone disorder (CKD-MBD)
CKD-MBD comprises of three major aspects—biochemical abnormalities, bone 
changes, and vascular calcifications [17].
4.1.1 Biochemical abnormalities in CKD-MBD
The biochemical abnormalities in CKD-MBD represent the laboratory aspect 
of the disorder. These include calcium level (ionized or total), phosphate level, 
PTH, alkaline phosphatase (total or bone specific), and VD status (25VD). Other 
indicators, such as 1,25VD and FGF-23 are not measured routinely. The earliest 
changes occur in PTH and VD metabolites—the abnormal values for PTH, 25VD 
and 1,25VD are detected in eGFR<60 ml/min/1.73 m2, whereas abnormal calcium 
and phosphate levels are detected in eGFR below 40 and remain stable until 
eGFR<20 ml/min/1.73 m2 [18].
According to the current guidelines, testing for calcium, phosphate, PTH, and 
alkaline phosphatase should be initiated in eGFR<60 ml/min/1.73 m2; the frequency 
of laboratory evaluation should be based on the rate of CKD progression, the 
magnitude of abnormalities, and the evaluation of treatment’s effectivity. Similarly, 
25VD should be tested in patients with eGFR<60 ml/min/1.73 m2 and frequency of 
testing depends on baseline values and therapeutic interventions [17]. The timing 
and frequency suggested by Kidney Disease: Improving Global Outcomes (KDIGO) 
are summarized in Table 2.
4.1.2 Bone disorders in CKD-MBD
Bone involvement in CKD [renal osteodystrophy (ROD)] is of pivotal 
importance, as it is associated with bone fractures (asymptomatic or symptom-
atic), bleeding, chronic disability, poorer life quality, and higher mortality in 
renal disease. In children with CKD, it leads to growth retardation and skeletal 
deformities [17].
Several types of bone histological changes can be detected in CKD, according 
to three major histological indicators: turnover, mineralization, and volume. Bone 
turnover (T) is a parameter, corresponding to bone formation rate. It can be abnor-
mally low, normal, or very high and is best assessed via bone biopsy and tetracycline 
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labeling. Mineralization (M) is the second parameter. Normally, the osteoblasts lay 
down new collagen and direct mineralization of the matrix. This process is impaired 
in CKD, leading to thickened osteoid. Mineralization is measured by osteoid matu-
ration time and mineralization lag time. The osteoid maturation time is the osteoid 
width divided by the distance between labels per day. The mineralization lag time 
is the osteoid maturation time adjusted for the percentage of osteoid surface that 
has a tetracycline label. Mineralization is classified as normal and abnormal. Bone 
volume (V) sums up bone formation and resorption rates. It is generally accepted 
that bone volume is expressed as bone volume per tissue volume and is classified as 
low, normal, and high bone volume.
According to the TMV classification of bone histology in CKD, the following 
ROD categories are recognized [19]:
1. Adynamic bone disease (AD)—low-turnover bone disease with normal miner-
alization. Volume can be low, but in some patients with normal mineralization 
and low turnover, it will be normal. AD is usually associated with PTH over-
suppression, including overdose of VD analogs or calcitriol
2. Mild secondary hyperparathyroidism related bone disease (MHPTBD)—medi-
um-to high bone turnover, any bone volume, normal mineralization
3. Osteitis fibrosa (OF)—represents a more advanced form of high-turnover dis-
ease, compared to MHPT, any bone volume and normal mineralization
4. Osteomalacia (OM)—low-turnover bone with abnormal mineralization. The 
bone volume may be low to medium, depending on the severity and duration 
of the process and other factors that affect bone health
5. Mixed uremic osteodystrophy (MUO)—represents features of the above men-
tioned variants; for example, a combination of high-turnover, normal bone 
volume, with abnormal mineralization
In addition, age related/postmenopausal osteoporosis can be detected. 
Measurement of bone mineral density [by using dual-energy X-ray absorpti-
ometry (DXA)] is most informative in CKD stages 1–2; in these cases, low BMD 
is associated with osteoporosis and treatment is performed as in the general 
population. Patients with low BMD and CKD stages 3–5 are designated as having 
CKD-MBD with low BMD. Recent reports demonstrate that BMD testing can 
predict fracture risk in eGFR<60 ml/min/1.73 m2. The current KDIGO guidelines 
broaden the indications for BMD testing in CKD stages 3–5D to assess fracture 
risk, if it will have effect on treatment. Finally, normal histology is also possible 
[17, 20].
Indicator CKD stage 3 CKD stage 4 CKD stage 5 and on dialysis 
(CKD 5D)
Calcium and phosphorus 6–12 months 3–6 months 1–3 months
PTH and alkaline phosphatase Baseline 6–12 months 3–6 months
25-Hydroxyvitamin D Baseline Baseline Baseline
CKD, chronic kidney disease; PTH, parathyroid hormone.
Table 2. 
Suggested testing for biochemical indicators of CKD-MBD according to CKD stage.
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It should be noted that histological findings differ according to renal replace-
ment type. In patients on hemodialysis OF and MUO are the most common find-
ings, in peritoneal dialysis–AD is detected in up to 50%, whereas in patients in CKD 
stages 3–5 not on dialysis the most common findings are OF and MUO. However, in 
the latter group, the highest percentage of normal histology is detected [20].
Bone biopsy is regarded as the golden standard for the precise diagnosis of the 
bone changes in CKD-MBD. Indications for bone biopsy are bone fractures, bone 
pain, unexplained hypercalcemia/hypophosphatemia, evaluation of the type of 
bone turnover (which may lead to treatment correction), and suspected aluminum 
toxicity. Planning antiresorptive treatment in eGFR<30 ml/min/1.73 m2 is currently 
not an indication for bone biopsy, as no evidence exists, linking bisphosphonate use 
to higher AD prevalence in CKD [17]. The most widely recognized disadvantages 
Clinical 
presentation
HTMBD LTMBD
Arthralgia Arthralgia
Bone pain Bone pain
Calciphylaxis Calciphylaxis
Bone fractures Bone fractures
Muscle weakness, spasms, tetany, paresthesia, 
convulsions (hypocalcaemia)
Aluminum toxicity—anemia, 
dementia
Vomiting, nausea, hypertension 
(hypercalcemia)
Vomiting, nausea, hypertension 
(hypercalcemia)
Pruritus Pruritus
Myalgia
Laboratory HTMBD LTMBD
Serum calcium N in early stages
↓/N/↑ in advanced HTMBD
Early stages N/↑
Advanced stages—↑↑
Serum phosphate N in early stages
N to very high in advanced stages
Early stages N/↓
Advanced—↓/↑
BAP N in early stages
↑ in advanced HTMBD
Early stages N/↓
Advanced—↓
PTH N/↑ in early stages
↑↑↑ in advanced HTMBD
Early stages N/↓
Advanced stages ↓
Radiology HTMBD LTMBD
Subperiosteal erosions—hands, clavicles, and 
pelvis
Fractures
Vertebral osteosclerosis Looser zones
Brown tumors Bone deformities
Extraskeletal calcifications Osteopenia and osteoporosis
Histology HTMBD LTMBD
OF, MHPTBD AD, OM
PTH, parathyroid hormone; BAP, bone specific alkaline phosphatase; N, normal; ↓, decreased; ↑, increased values; 
OF, osteitis fibrosa; MHPTBD, mild secondary hyperparathyroidism related bone disease; AD, adynamic bone 
disease; OM, osteomalacia.
Table 3. 
Clinical presentation, laboratory, radiologic and histologic findings in low turnover mineral bone disease 
(LTMBD) and high turnover mineral bone disease (HTMBD).
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of the procedure are pain, laborious procedure, time-consuming, and expensive 
histological evaluation, as well as insufficient histopathological expertise [21].
These limitations restrict the wide use of bone biopsy. Therefore, markedly elevated 
PTH and bone-specific alkaline phosphatase can be used in clinical practice to predict 
bone turnover in CKD-MBD. Thus, two types of mineral bone diseases are defined—
high turnover mineral bone disease (HTMBD) and low turnover mineral bone disease 
(LTMBD). In cases, in which clinical and laboratory data are inconclusive of the type of 
bone turnover, bone biopsy should be considered [17]. The clinical, laboratory, radio-
logical, and histological characteristics of the both entities are summarized in Table 3.
4.1.3 Vascular calcification in CKD-MBD
Vascular calcification (VC) is deposition of calcium phosphate in vascular tis-
sues. It presents with calcification of arterial media, intima, valves, and rarely with 
calcific uremic arteriolopathy (calciphylaxis). Normally, this occurs with aging. 
However, the process is accelerated in CKD and leads to increased mortality and 
morbidity. Initially, it was regarded as a finding in patients with end-stage renal 
disease (ESRD), but currently, it is detected in early CKD stages in adults and in 
children with ESRD, thus depicting a more complicated picture [22].
Patients with VC are regarded as having the highest risk for cardiovascular 
events. The diagnosis is based on abdominal lateral radiograph (vascular calcifica-
tions), echocardiogram (valvular calcifications), or computer tomography [17].
The association of VC with VD status in CKD is not well defined as contradicting 
reports exist. Two report demonstrate, that lower serum 1,25VD is associated with 
increased risk for and demonstrated that 25VD has no association with VC [23, 24]. 
As arterial stiffening is regarded as related pathology to VC in CKD, it should be 
noted that two recent interventional studies demonstrated improvement of endo-
thelial dysfunction in CKD patients after cholecalciferol supplementation [25–27]. 
Higher serum levels of 1,25VD and high doses of VD supplementation increased the 
risk for VC [23, 28], thus indicating the dual role of VD in vascular health.
Finally, the type of VD treatment may be important too. Generally, vitamin 
D analogs (VDA) demonstrate similar effectivity in reduction of PTH levels to 
calcitriol, with lower toxicity—lower rates of hypercalcemia and hyperphosphate-
mia, thus suggesting lower risk for supplementation-enhanced VC. Unfortunately, 
more trails are needed to evaluate the effect of different supplementation types 
on VC prevalence. In addition, new VDA are being evaluated in the treatment of 
CKD-MBD, with more expressed cardiac protection and less hypercalcemia and 
hyperphosphatemia than paricalcitol [29–31].
4.2 VD pleiotropy in renal disease
As mentioned above, the VDR and the enzyme CYP27B1 have wider distribution 
in the body and are being expressed in organs not involved in calcium-phosphate 
metabolism. This indicates a greater physiological importance of the VD axis, span-
ning beyond skeletal physiology. These extraskeletal properties are designated as 
pleiotropic effects of VD. In this sub-section, the current knowledge of VD pleiot-
ropy in CKD patients will be presented.
4.2.1 VD pleiotropy in CKD: proteinuria and CKD progression
Poorer VD status was associated with higher proteinuria and faster progres-
sion of CKD. In addition, VDR activation was found to slow CKD progression in 
immune and non-immune renal diseases.
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In IgA nephropathy, human studies associated poorer VD status with poorer 
clinical outcomes [32]. In addition, calcitriol supplementation suppressed pro-
teinuria in IgA patients by activating the VDR and thus influencing cytokine and 
leukotriene metabolism [33].
Recent studies demonstrated the importance of VD axis in systemic lupus 
erythematosus (SLE) and lupus nephritis (LN). Poorer VD status correlated with 
higher SLE activity, whereas poorer VDR expression in renal tissue was linked to 
higher renal activity and more severe renal lesions in patients with LN [34, 35]. 
Podocyte autophagy is a key factor in renal involvement in LN. A recent study 
showed that poorer VD status correlated with higher podocyte autophagy activity 
and VD effectively suppressed it in LN, thus protecting podocytes from antibody-
mediated injury [36]. VD and VDR affect autophagy via different mechanisms: acti-
vating calcium-dependent intracellular kinases, downregulating mTOR expression, 
or upregulation of the cyclin-dependent kinase inhibitor p19INK4D [37].
However, VD has renoprotective effect in non-immune glomerular diseases too. 
In diabetic nephropathy (DN), both animal models and clinical trials demonstrate 
the negative correlation between low VD and the risk for DN and DN progression, 
as well as the beneficial effect of VD/VD analogs in reducing albuminuria, renal 
fibrosis, thus retarding disease progression [38, 39]. The effect can be explained with 
RAS suppression, suppression of inflammatory mediators [nuclear factor-kappa B 
(NF-κB), transforming growth factor-β(TGF-β)], suppressing the Wnt/β-catenin 
pathway, which is involved in epithelial to mesenchymal cell transition (EMT) in 
high glucose milieu, as well as upregulation of nephrin expression [39–41].
The mechanisms mentioned in DN (suppression of RAS, inflammation, EMT) 
are the basis of renal protection of VD in other renal diseases–in animal models and 
human clinical trials [33]. Additionally, an inverse correlation between VD status 
and proteinuria and blood pressure control in autosomal polycystic kidney disease 
(ADPKD) was reported, as well as reduction of proteinuria and hypertension on 
treatment with VDR agonist in experimental PKD. However, the findings are to be 
evaluated prospectively in interventional study in patients with ADPKD [42].
4.2.2 VD pleiotropy in CKD: autoimmunity, inflammation, and infection
The presence of VDR and CYP27B1 has been well recognized in the immune 
cells, which modulate their differentiation and proliferation. VD suppresses B-cell 
proliferation, modulates T-helper proliferation, favoring the T-helper type 2 sub-
type, thus suppressing inflammatory cytokine synthesis (IL17, IL21) and stimulat-
ing the production of anti-inflammatory ones (IL10). In addition, VD enhances the 
production of cathelicidin and β-defensin 2, as well as influences autophagy and 
apoptosis [33, 43]. All these properties of VD and VDR demonstrate the importance 
of VD axis in protective and pathological immunity.
4.2.2.1 VD and autoimmunity/inflammation
The role of VD in LN has been already discussed. Other studies, evaluating the 
VD–SLE association demonstrate that poorer VD is related to higher SLE activity 
in adults and children [44]. Different supplementation regimens also demon-
strated improvement in inflammatory markers, disease activity indices, decrease 
in T-helpers types 1 and 17 [44]. However, despite the different papers, reporting 
beneficial effect from VD, a recent study demonstrated increase of SLE activity 
after exposing patients to UV radiation, despite improvement in VD status [45]. 
Thus, the SLE-VD correlation still remains to be clarified.
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The rheumatoid arthritis (RA) and the inflammatory bowel disease (IBD) are 
diseases that influence kidney health by causing AA amyloidosis, which in turn 
progresses to ESRD. VD status was inversely associated with RA disease activity 
and RA-associated complications [46]. However, despite some reports, indicating 
beneficial effect of VD supplementation on T-helper 17 function, the results for VD 
supplementation currently are inconsistent [46, 47].
Several studies demonstrated lower VD status in patients with more aggressive 
IBD. However, the findings may be attributed to lower absorption of VD due to the 
active intestinal inflammation, especially in Crohn’s disease [48, 49]. Interventional 
studies also demonstrated the beneficial effect of VD supplementation in suppress-
ing pro-inflammatory markers in IBD. Yet, the importance of VD in IBD remains to 
be clarified [50, 51].
4.2.2.2 VD and infection
Infection is a well-recognized leading cause for death in CKD patients, especially 
those on dialysis. It was already mentioned that the VD axis plays a role in immunity 
by enhancing cathelicidin production. In dialysis patients, low cathelicidin levels were 
detected, which were associated with higher risk for infection and also modest corre-
lation to 1,25VD levels was discovered [52]. Interventional studies also demonstrated 
the decreased risk for infection in dialysis patients. VD supplementation reduced 
significantly the risk for hospitalization due to acute respiratory infections in hemo-
dialysis (HD) patients; in another study, VD supplementation decreased the risk for 
peritonitis in patients on peritoneal dialysis (PD) [53, 54]. A more recent study also 
demonstrated decrease in infection rates in dialysis patients treated with VDR analogs 
[55]. In contrast to these findings, Yildirim et al. failed to demonstrate a significant 
relation between VD status and inflammatory markers in CKD patients [56].
4.2.3 VD pleiotropy in CKD: neoplasia
An already mentioned paper demonstrated reduced malignancy-associated 
mortality in VDA-treated dialysis patients. However, the study did not evaluate 
the specific localization of the neoplasia, nor its histology [55]. Therefore, in this 
subsection, the most common malignant diseases will be reviewed and their asso-
ciation with VD. Unfortunately, the exact association between VD and neoplasia in 
CKD patients is not well evaluated, as CKD patients are usually excluded from large 
trials and registries [57].
4.2.3.1 Breast cancer
The reports evaluating the association between VD deficiency and breast cancer 
are inconsistent. The inverse association between breast cancer and VD, detected in 
several studies was not supported by more recent prospective studies. In addition, 
a controversy exists about the beneficial effect of VD supplementation on breast 
cancer risk and survival [44]. Unfortunately, the cited studies did not demonstrate 
data for CKD patients.
4.2.3.2 Colorectal cancer
Several studies demonstrate an inverse correlation between colorectal cancer 
and 25VD levels [58, 59]. The findings do not correspond to the results of a larger 
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study, detecting no significant association between colorectal cancer and VD status 
[60]. Unfortunately, the data from interventional trails with VD supplementation 
also have conflicting result for the effect of VD on colorectal cancer prevention and 
survival improvement [44, 61]. Similarly to breast cancer, the data for the associa-
tion between colorectal cancer and VD status in renal patients is limited.
4.2.3.3 Other neoplasms
The results about the influence of VD on the risk for other malignancies are 
controversial. A large study (n = 70,563) evaluated the association of 25VD levels on 
the risk for prostate cancer, breast cancer, lung cancer, pancreatic cancer, colorectal 
cancer, ovarian cancer, and neuroblastoma. 25VD concentrations did not corre-
spond to the risk for any of the mentioned neoplasias. Therefore, the authors do not 
support the regular VD screening as an attempt for cancer prevention [62]. In addi-
tion, a large multicenter study in patients on hemodialysis also did not demonstrate 
significant association between total cancer prevalence and VD deficiency [63].
Multiple myeloma (MM) is a plasma cell disease that often presents with 
kidney manifestations. Several studies reported high rates of VD deficiency in MM 
patients and specific alleles for VDR were associated with higher risk for MM [64, 
65]. Lauter and Schmidt-Wolf established that lower VD levels were associated 
with more expressed plasma cell infiltration of the bone marrow. In this study, VD 
supplementation improved anemia, led to higher white blood cell and lower platelet 
count [66]. Yet, the risk for hypercalcemia should be taken into consideration when 
VD supplementation is applied in MM patients.
4.2.4 VD pleiotropy in CKD: diabetes mellitus, cardiovascular disease (CVD)
4.2.4.1 VD and diabetes mellitus
Basic science studies demonstrated improvement in glucose metabolism due 
to immunomodulatory effect (especially in diabetes type 1), improvement of β 
cell function by increase in insulin secretion, and decreasing insulin resistance by 
stimulating insulin receptor expression via activating the VDR. Other mechanisms 
such as RAS suppression and anti-inflammatory effect of VD were also taken into 
consideration. However, observational studies do not establish clear relationship 
between VD status and DM prevalence, as some studies support the association, 
whereas others do not [44]. Interventional trials also have conflicting results. 
Two recent prospective studies showed improvement in glucose metabolism after 
vitamin D supplementation was applied [67, 68]. Unfortunately, the studies did not 
evaluate patients with renal disease. Two interventional studies with paricalcitol 
failed to detect improvement in insulin resistance in patients CKD stages 3 and 4 
and in dialysis [69, 70].
4.2.4.2 VD and cardiovascular disease (CVD)
CVD is a leading cause for mortality in CKD. As VDR and 27CYPB1 are 
expressed in the cells of the cardiovascular system, it could be expected that the VD 
axis can play a beneficial role in cardio-vascular health. A possible cardioprotection 
can be explained with RAS suppression and anti-inflammatory effects; VDR activa-
tion can improve cardiac muscle cells contractility and modulate their proliferation 
and growth. In addition, VD can improve peripheral vascular health by affecting 
endothelial and smooth muscular cells too [71].
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Even though the association between VD deficiency and CVD has been recognized 
in the general population and in CKD, large randomized interventional studies failed 
to demonstrate improvement from VD supplementation in cardiovascular outcomes, 
cardiac structure, or function in CKD patients [72]. An improvement in blood pres-
sure control and endothelial function (as measured by brachial artery flow-mediated 
dilatation) was observed after VD supplementation in the general population; 
however, in CKD patients, no significant antihypertensive effect was detected [73]. 
Similarly, the results for the effect on VD supplementation on arterial stiffness and 
endothelial function are conflicting [72, 73]. Therefore, the use of VD in renal disease 
in order to improve cardiovascular events is currently not recommended [72].
4.2.5  VD pleiotropy in CKD: muscle health, cognitive function, peritoneal fibrosis, 
and anemia
4.2.5.1 Muscle health and cognitive function
In hemodialysis (HD) patients, a positive relationship between muscle strength 
and VD levels was detected, with optimal handgrip strength in 25VD above 30 ng/
ml (75 nmol/L). In ESRD patients, suboptimal VD was associated with lower quad-
riceps mass and increased risk for falls [74]. In addition, in PD patients, low 25VD 
was found to be the independent factor for global cognitive impairment due to the 
antioxidant and neuroprotective role of 1,25VD. This is of crucial importance, as 
PD is a home-based renal replacement therapy that needs adequate cognition and 
self-monitoring [75].
4.2.5.2 Anemia and peritoneal fibrosis
Treatment with VDA led to the improvement of anemia in ESRD patients. A pos-
sible mechanism is suppression of inflammation and direct stimulation of erythro-
poiesis. In addition, paricalcitol reduced PD-associated thickening of the peritoneum 
and prevented peritoneal fibrosis in animal models. However, recent study in PD 
patients did not detect any benefit from paricalcitol supplementation in preventing 
peritoneal remodeling. In contrast to these results, Kerschbaum et al. demonstrated 
protective effect of oral active VD against peritonitis in PD patients [33, 54, 76].
5. Vitamin D deficiency after kidney transplantation
Suboptimal 25VD is a commonly detected problem after kidney transplanta-
tion (KT) with prevalence above 80% of the kidney transplant recipients (KTRs). 
As KTRs are CKD patients, all mentioned factors, predisposing to impaired VD 
metabolism are valid for this cohort of patients, especially considering the fact that 
more than 50% of the KTRs have GFR<60 ml/min/1.73 m2. In addition, transplant-
specific factors influence VD synthesis: sun exposure avoidance due to the increased 
risk for skin malignancies, use of sun-protecting cosmetics (limiting further UV 
exposure), proteinuria after KT (increased loss in urine), higher prevalence of 
obesity after KT (reduced bioavailability), the presence of new onset diabetes after 
transplantation (NODAT) (by reducing intestinal absorption), use of steroids 
(increased 1,25VD catabolism), and calcineurin inhibitors (impaired 25VD liver 
synthesis) [77, 78]. Similarly to CKD in native kidneys, the VD-associated clinical 
implications after KT are categorized as post-transplant mineral bone disorder 
(PTMBD) and VD pleiotropy.
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5.1 Post-transplant mineral bone disorder
Similarly to native kidneys, PTMBD consists of three aspects—biochemical 
abnormalities, bone involvement, vascular pathology and is associated with higher 
risk for fractures and death.
5.1.1 PTMBD: biochemical abnormalities
Significant changes occur in the biochemical indicators of calcium-phosphorus 
metabolism after KT. In the early post-transplant period, the fluctuations in the 
parameters are more pronounced as the graft function is rapidly changing. Due to 
the presence of functioning renal tubules and still high levels of PTH and FGF-23, 
hypophosphatemia and mild hypercalcemia are common. These changes usually 
normalize within months after KT as graft function stabilizes. Therefore, the 
current KDIGO guidelines recommend at least weekly testing for calcium and 
phosphorus immediately after KT [17]. FGF-23 and PTH rapidly decrease; however, 
PTH may be significantly elevated years after successful KT due to parathyroid cell 
hypertrophy. VD levels are low in the early post-transplant period; yet, suboptimal 
levels are very common later after KT [78].
In the late post-transplant period, current guidelines recommend the testing for 
calcium, phosphorus, PTH, and alkaline phosphatase to be performed according 
to the magnitude of the abnormalities, rate of progression of post-transplant CKD, 
and the presence of medical treatment. Practically, the timing is similar to patients 
with CKD stage 3–5 with native kidneys (see Table 2). 25VD should be tested at 
baseline and repeated testing should be performed according to the initial level and 
the presence of medical interventions. In our center, 25VD levels are monitored 
twice annually, taking into consideration its seasonal variations in the general popu-
lation. Thus, a significant deterioration of VD status in the winter/fall was detected, 
allowing adequate seasonal supplementation to be initiated.
5.1.2 PTMBD: bone disease
Post-transplant bone disease is commonly observed after KT and encompasses 
ROD, osteoporosis, bone fractures, and osteonecrosis. Deterioration in BMD occurs 
mainly during the first 12 months, though BMD loss persists at lower rates after the 
first post-transplant year. The etiology is multifactorial: pre-existing CKD-MBD, 
duration of dialysis and transplantation, poor graft function, hypogonadism, 
higher rates of diabetes after KT, suboptimal VD levels, and use of immunosup-
pressive agents. Of these, steroids are of particular importance as their cumulative 
and mean dose is associated with decreased bone formation and bone density. Some 
reports indicate that calcineurin inhibitors can rise PTH levels and increase the risk 
of osteoporosis, but the findings are not uniformly accepted [17, 79].
In KTRs, not only fracture prevalence is significantly increased compared to the 
general population, but also fracture-associated complications, including mortality, 
are more common in the post-transplant setting. Major fracture sites are the hip 
(usually osteoporosis-associated) and the ankle/foot (atypical for osteoporosis), 
which demonstrate that both ROD and osteoporosis play an important role in bone 
fragility [80].
The use of DXA–BMD measurement is getting more attention in native CKD, 
as a growing body of evidence demonstrates that it can predict fracture risk across 
CKD categories. To date, only one retrospective study, total hip DXA measurement 
after KT was associated with increased fracture risk. In addition, a recent prospec-
tive study had similar findings [81, 82]. Despite the insufficient evidence for KTRs, 
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KDIGO suggests the use of BMD testing in all stages of post-transplant CKD in 
KTRs with high risk for osteoporosis, if the measurement will have effect on treat-
ment. Bone biopsy can be considered to guide treatment [17].
5.1.3 PTMBD: vascular calcifications
VC is common after KT and is usually associated with pre-transplant uremia. 
In addition, most studies are semi-quantitative, thus making post-transplant VC 
progression assessment difficult. However, there are studies demonstrating a stop 
in progression or even improvement in VC in KTRs [83, 84]. Recognized risk factors 
for VC after KT are statin use, low 25VD levels, male sex, older age, and higher 
phosphate levels [85]. The data for the effect of immunosuppressive agents are 
conflicting. Mycophenolates proved to have protective effects against calcification, 
especially compared to steroids and calcineurin inhibitors; rapamycin suppressed 
smooth muscle cell proliferation, whereas everolimus impaired the vasoactive and 
antithrombotic function of the endothelium [86]. Therefore, more studies are 
needed in order to evaluate the effect of KT on VC.
5.2 VD pleiotropy after kidney transplantation
The graft survival at the tenth year after KT is significantly lower than the 
survival during the first 12 months. The explanation for these unsatisfactory results 
is poorer patient survival due to neoplasia, CVD, NODAT, calcineurin toxicity. It 
could be hypothesized that VD can improve graft and patient survival due to its 
pleiotropy. However, the trials in KTRs are small in number and in size, thus further 
research in this sphere is warranted.
5.2.1 VD pleiotropy after KT: proteinuria and renal protection
Observational studies linked poor VD status to poorer graft outcomes [86]. Our 
results also demonstrated that higher VD is associated with lower post-transplant 
proteinuria [87]. However, interventional studies did not fully support the VD–
graft function association. Cholecalciferol supplementation failed to demonstrate 
renoprotection in prospective study [88]. However, in a recent prospective placebo-
controlled study, paricalcitol ameliorated proteinuria in KTRs [89].
5.2.2 VD pleiotropy after KT: rejection
Observational studies demonstrated higher rates of acute rejection in VD defi-
cient KTRs [90]. Unfortunately, interventional studies did not find protective role 
of cholecalciferol supplementation on rejection prevalence [88]. Therefore, the role 
of VD in rejection prevention after KT is not fully understood and is under debate.
5.2.3 VD pleiotropy after KT: infection
Infection is a major cause for death after KT. Several recent reports established 
negative correlation between VD status and infection risk, especially for cytomega-
lovirus and BK virus infections in KTRs [91, 92]. However, our observational study 
showed no association between VD status and prevalence of urinary tract infections 
after KT [93]. Furthermore, the VITA-D study did not establish positive effect of 
cholecalciferol supplementation on infection risk [88]. A probable explanation for 
the discrepancies in the studies are the different types of infection evaluated (e.g. 
in the VITA-D study the total infection risk was assessed). Probably, a more specific 
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approach should be chosen and the infection risk for specific etiological agent and 
its association to VD should be analyzed.
5.2.4 VD pleiotropy after KT: malignancies
Despite the anti-neoplastic properties of VD in vitro and in animal models, the 
evidence for anti-malignancy effect of VD in CKD patients and KTRs is insufficient. 
Observational studies report conflicting results for the association between post-
transplant malignancies and VD status [86]. A recent study in our transplant center 
showed that VD-deficient KTRs had higher prevalence of non-cutaneous cancers [94]. 
A single center study established beneficial effect from active VD supplementation on 
post-transplant neoplasia rates [95]. The larger prospective, multicenter, double-blind, 
randomized, controlled study VITALE is currently being performed, which will evalu-
ate the effect of cholecalciferol supplementation on malignancy risk after KT [96].
5.2.5 VD pleiotropy after KT: NODAT
The major risk factors for NODAT are use of steroids and calcineurin inhibi-
tors. The data for VD-NODAT association are insufficient. The trial VITALE is to 
assess the effect of high and low doses cholecalciferol in VD–insufficient KTRs on 
NODAT prevalence [96].
5.2.6 VD pleiotropy after KT: cardiovascular disease
Marchal et al. established a significant association between lower 25VD and vascu-
lar calcification after KT [85]. However, a more recent study did not find a relationship 
between VD status and post-transplant hypertension and major CV events [97]. One 
of the aims of the already mentioned trial VITALE is to assess the effect of cholecalcif-
erol supplementation on blood pressure control and CVD rates in KTRs [96].
6. Treatment of vitamin D deficiency in renal disease
6.1 Treatment with cholecalciferol, ergocalciferol, calcitriol, VDA
Supplementation with cholecalciferol (vitamin D3), ergocalciferol (vitamin D2), 
or treatment with the active vitamin D calcitriol or VDA suppresses PTH in secondary 
hyperparathyroidism in CKD. As a first step, a correction of hypocalcemia, hyper-
phosphatemia, and suboptimal 25VD levels should be performed. In more advanced 
CKD-related secondary hyperparathyroidism calcitriol and VDA can be initiated. It 
should be noted that over-suppression of the parathyroid gland due to overdose of 
the VD treatment is a major cause for AD. Therefore PTH, as well as serum phosphate 
and calcium, should be regularly monitored. It should be noted that the optimal PTH 
values for dialysis patients are two times up to nine times the upper normal limit, 
whereas for patients not on dialysis the optimal range is not established. If trend for 
lowering/rising values is present, changes in treatment should be changed so that the 
negative trends be reverted [17]. Similarly, in KTRs cholecalciferol/calcitriol/VDA 
treatment should also take these trends into consideration.
6.1.1 Supplementation with cholecalciferol/ergocalciferol
In the general adult population, supplementation doses of VD at least 
600 IU daily; however, if improvement in VD status is needed, doses of at least 
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1500–2000 IU per day should be prescribed. The maximal dose VD without medical 
supervision should be 4000 IU daily. Cholecalciferol and ergocalciferol are equally 
effective [98]. The KDIGO guidelines recommend VD deficiency in CKD patients 
and in KTRs to be treated as in the general population. It is the initial therapeutic 
step, together with correction of hypocalcemia and hyperphosphatemia, as it effec-
tively suppresses PTH in CKD stages 3–5 not on dialysis. More aggressive approach 
is to be avoided as modest PTH elevation is regarded as adaptive mechanism in 
declining GFR [17].
6.1.2 Treatment with calcitriol and VDA
Calcitriol is naturally existing 1,25VD, whereas VDA are synthetic deriva-
tives of vitamin D2 (paricalcitol, doxercalciferol) and vitamin D3 (alfacalcidol, 
falecalcitriol, 22-oxacalcitriol). Despite the existing trials demonstrating positive 
effect of calcitriol/VDA on biochemical abnormalities, more recent studies do not 
demonstrate improvement in patient-centered end-points, such as left ventricular 
mass index and heart function; however, hypercalcemia was observed. Taking into 
account that modest PTH elevation is a possible adaptive response in CKD, the lack 
of significant clinical effects and higher risk for hypercalcemia, the use of calcitriol 
and VDA is not routinely recommended in CKD stages 3–5 not on dialysis. Their use 
is advocated in cases of severe and progressive secondary hyperparathyroidism and 
eGFR below 30 ml/min/1.73 m2 or dialysis patients [17].
The data for hypercalcemia rates in calcitriol and VDA are conflicting. Zand 
et al. demonstrated lower hypercalcemia prevalence in patients treated with parical-
citol; other reports established no difference in hypercalcemia between calcitriol 
and paricalcitol [29, 99].
6.1.3 Other therapeutic measures
Other measures, recommended by KDIGO that optimize VD treatment in CKD-
MBD are avoidance of hypercalcemia, reduction of phosphate serum levels, including 
phosphate dietary restriction, limitation of the use of calcium-based phosphate bind-
ers, calcium dialysate concentrations within the range of 1.25 and 1.50 mmol/l [17].
6.1.4 Novel agents
6.1.4.1 Calcifediol
Calcifediol is an oral 25-hydroxyvitamin D3. A study demonstrated reduction 
in PTH levels without changes in phosphate, calcium, and FGF-23 levels in CKD 
patients. In this chapter, patient-related outcomes were not assessed [100]. Further 
trials are needed to clarify the use of calcifediol in renal disease.
6.1.4.2 Vitamin K
Vitamin K plays a crucial role in vascular health. It serves as a cofactor for 
γ-glutamyl carboxylation, which converts glutamate into γ-carboxyglutamate (Gla). 
In vitamin K insufficiency, which is common in CKD, higher levels of desphosphor-
ylated-uncarboxylated matrix Gla-protein (MGP) are established, which are associ-
ated with VC, as MGP serves as calcification inhibitor. Vitamin K supplementation 
increases MGP carboxylation. What is more, VD supplementation upregulates MGP 
synthesis, whereas vitamin K suppressed 1,25VD-associated calcinosis [101, 102]. 
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Therefore, it can be hypothesized that vitamin K supplementation in CKD can be 
an adjuvant treatment to VD supplementation and will decrease its adverse effects. 
Further research of the efficacy and safety of vitamin K supplementation in CKD is 
needed.
7. Conclusion
VD deficiency in renal patients has been a burning issue in nephrology for many 
years. Yet, many questions remain unanswered. Of particular interest are the effect 
on VD treatment on clinical outcomes, especially death and cardiovascular events; 
VD-associated adverse events in CKD; VD pleiotropy in renal disease (random-
ized controlled prospective interventional studies are needed); the use of novel 
therapeutic agents should be further evaluated (vitamin K, new VDA, calcifediol). 
In addition, new biomarkers, evaluating bone health in CKD and new techniques, 
evaluating BMD and fracture risk may guide VD treatment more accurately. 
Therefore, new diagnostic and therapeutic strategies can be expected in the future.
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